Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial.

MLA

Shen, Yifeng, et al. “Efficacy and Safety of Bupropion Hydrochloride Extended-Release versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.” Journal of Affective Disorders, vol. 257, Oct. 2019, pp. 143–49. EBSCOhost, https://doi.org/10.1016/j.jad.2019.07.023.

APA

Shen, Y., Zhao, Q., Yu, Y., Tan, Y., Zhang, H., Xu, X., Wang, Z., Li, Y., Hu, J., Zhong, J., & Li, H. (2019). Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. Journal of Affective Disorders, 257, 143–149. https://doi.org/10.1016/j.jad.2019.07.023

Chicago

Shen, Yifeng, Qian Zhao, Yimin Yu, Yunlong Tan, Honggeng Zhang, Xiufeng Xu, Zhiyang Wang, et al. 2019. “Efficacy and Safety of Bupropion Hydrochloride Extended-Release versus Escitalopram Oxalate in Chinese Patients with Major Depressive Disorder: Results from a Randomized, Double-Blind, Non-Inferiority Trial.” Journal of Affective Disorders 257 (October): 143–49. doi:10.1016/j.jad.2019.07.023.